☰

Hongyu Li - Publications

Affiliations: 
Pharmaceutical Sciences University of Arkansas for Medical Sciences, United States 
Tree Info Grants Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Zhang L, Moccia M, Briggs DC, Bharate JB, Lakkaniga NR, Knowles P, Yan W, Tran P, Kharbanda A, Wang X, Leung YK, Frett B, Santoro M, McDonald NQ, Carlomagno F, ... Li HY, et al. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. Journal of Medicinal Chemistry. 65: 1536-1551. PMID 35081714 DOI: 10.1021/acs.jmedchem.1c01280  0.788
2021 Zhang L, Lakkaniga NR, Bharate JB, Mcconnell N, Wang X, Kharbanda A, Leung YK, Frett B, Shah NP, Li HY. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. European Journal of Medicinal Chemistry. 225: 113776. PMID 34479037 DOI: 10.1016/j.ejmech.2021.113776  0.786
2021 Kharbanda A, Tran P, Zhang L, Leung YK, Li HY, Frett B. Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. European Journal of Medicinal Chemistry. 225: 113763. PMID 34419892 DOI: 10.1016/j.ejmech.2021.113763  0.711
2021 Moccia M, Yang D, Lakkaniga NR, Frett B, McConnell N, Zhang L, Brescia A, Federico G, Zhang L, Salerno P, Santoro M, Li HY, Carlomagno F. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Scientific Reports. 11: 16103. PMID 34373541 DOI: 10.1038/s41598-021-95612-4  0.719
2021 Kharbanda A, Zhang L, Saha D, Tran P, Xu K, Li MO, Leung YK, Frett B, Li HY. Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors. European Journal of Medicinal Chemistry. 223: 113660. PMID 34246853 DOI: 10.1016/j.ejmech.2021.113660  0.725
2021 Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry. 216: 113265. PMID 33652352 DOI: 10.1016/j.ejmech.2021.113265  0.709
2020 Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, et al. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of Clinical Investigation. PMID 33044225 DOI: 10.1172/JCI144618  0.633
2020 Wang H, Chen Y, Gu X, Xi J, Ren Z, Wang S, Duan Y, Li H, Zhu T, Du Y, Zhang X, Ma M. Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 inhibitors. Bioorganic & Medicinal Chemistry. 28: 115775. PMID 32992252 DOI: 10.1016/J.Bmc.2020.115775  0.31
2020 Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, et al. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of Clinical Investigation. 130: 5027. PMID 32870163 DOI: 10.1172/JCI142404  0.633
2020 Yan W, Lakkaniga NR, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li HY. Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of Medicinal Chemistry. PMID 32841014 DOI: 10.1021/Acs.Jmedchem.0C01351  0.686
2020 Lakkaniga NR, Gunaganti N, Zhang L, Belachew B, Frett B, Leung YK, Li HY. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry. 206: 112691. PMID 32823007 DOI: 10.1016/J.Ejmech.2020.112691  0.713
2020 Lakkaniga NR, Zhang L, Belachew B, Gunaganti N, Frett B, Li HY. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. European Journal of Medicinal Chemistry. 203: 112589. PMID 32717530 DOI: 10.1016/j.ejmech.2020.112589  0.713
2020 Storey AJ, Naceanceno KS, Lan RS, Washam CL, Orr LM, Mackintosh SG, Tackett AJ, Edmondson RD, Wang Z, Li HY, Frett B, Kendrick S, Byrum SD. ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. Molecular Omics. PMID 32347222 DOI: 10.1039/c9mo00149b  0.648
2020 Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Bioisosteric discovery of NPA101.3, a second generation RET/VEGFR2 inhibitor optimized for single-agent polypharmacology. Journal of Medicinal Chemistry. PMID 32298114 DOI: 10.1021/Acs.Jmedchem.9B01336  0.72
2020 Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. Correction: One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chemical Communications (Cambridge, England). PMID 32031562 DOI: 10.1039/d0cc90063j  0.615
2020 Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chemical Communications (Cambridge, England). PMID 31971170 DOI: 10.1039/C9Cc08220D  0.669
2020 Li F, Frett B, Li HY. Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/C. Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry. 25: 1403-1408. PMID 26843785 DOI: 10.1055/S-0033-1339025  0.613
2019 Lakkaniga NR, Balasubramaniam M, Zhang S, Frett B, Li HY. Structural Characterization of the Aurora Kinase B "DFG-flip" Using Metadynamics. The Aaps Journal. 22: 14. PMID 31853739 DOI: 10.1208/s12248-019-0399-6  0.663
2019 Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY. The Exploration of Chirality for Improved Druggability within the Human Kinome. Journal of Medicinal Chemistry. PMID 31550151 DOI: 10.1021/acs.jmedchem.9b00640  0.702
2018 Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chemical Communications (Cambridge, England). PMID 30375586 DOI: 10.1039/c8cc07063f  0.649
2018 Frett B, McConnell N, Kharbanda A, Naresh G, Rounseville B, Warner C, Chang J, Debolske N, Li HY. Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-]pyridine derivatives. Tetrahedron. 74: 4592-4600. PMID 30344351 DOI: 10.1016/J.Tet.2018.07.027  0.647
2018 Yan W, Lakkaniga NR, Carlomangno F, Santoro M, McDonald N, Lv F, Gunaganti N, Frett B, Li HY. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of Medicinal Chemistry. PMID 30188734 DOI: 10.1021/Acs.Jmedchem.8B01092  0.705
2018 He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG. Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells. Bioorganic & Medicinal Chemistry. PMID 29921474 DOI: 10.1016/j.bmc.2018.06.010  0.689
2018 Bharate JB, McConnell N, Naresh G, Zhang L, Lakkaniga NR, Ding L, Shah NP, Frett B, Li HY. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Scientific Reports. 8: 3722. PMID 29487300 DOI: 10.1038/S41598-018-21839-3  0.721
2017 McConnell N, Xu Z, Kumarasamy V, Sun D, Frett B, Li HY. Synthesis of Constrained Heterocycles Employing Two Post-Ugi Cyclization Methods for Rapid Library Generation with In Cellulo Activity. Chemistryselect. 2: 11821-11825. PMID 30140731 DOI: 10.1002/slct.201702179  0.668
2017 De Falco V, Carlomagno F, Li HY, Santoro M. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice & Research. Clinical Endocrinology & Metabolism. 31: 307-318. PMID 28911727 DOI: 10.1016/j.beem.2017.04.013  0.36
2017 Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, et al. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of Clinical Investigation. PMID 28737508 DOI: 10.1172/Jci89092  0.7
2016 Xi JB, Fang YF, Frett B, Zhu ML, Zhu T, Kong YN, Guan FJ, Zhao Y, Zhang XW, Li HY, Ma ML, Hu W. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. European Journal of Medicinal Chemistry. 126: 1083-1106. PMID 28039836 DOI: 10.1016/J.Ejmech.2016.12.026  0.705
2015 Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, Li HY. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. Angewandte Chemie (International Ed. in English). 54: 8717-21. PMID 26126987 DOI: 10.1002/anie.201501104  0.726
2015 Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. European Journal of Medicinal Chemistry. 94: 123-31. PMID 25765758 DOI: 10.1016/J.Ejmech.2015.02.052  0.728
2015 Wang Y, Frett B, McConnell N, Li HY. Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral media. Organic & Biomolecular Chemistry. 13: 2958-64. PMID 25611884 DOI: 10.1039/c4ob02284j  0.599
2014 Frett B, McConnell N, Wang Y, Xu Z, Ambrose A, Li HY. Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies. Medchemcomm. 5: 1507-1514. PMID 26843921 DOI: 10.1039/C4MD00251B  0.704
2014 Frett B, Moccia M, Carlomagno F, Santoro M, Li HY. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. European Journal of Medicinal Chemistry. 86: 714-23. PMID 25232968 DOI: 10.1016/j.ejmech.2014.09.023  0.703
2014 Wang Y, Frett B, Li HY. Efficient access to 2,3-diarylimidazo[1,2-a]pyridines via a one-pot, ligand-free, palladium-catalyzed three-component reaction under microwave irradiation. Organic Letters. 16: 3016-9. PMID 24854606 DOI: 10.1021/ol501136e  0.615
2014 Frett B, Brown RV, Ma M, Hu W, Han H, Li HY. Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition. Journal of Medicinal Chemistry. 57: 5835-44. PMID 24517277 DOI: 10.1021/jm401719n  0.694
2013 Frett B, Wang Y, Li HY. Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage? Chemmedchem. 8: 1620-2. PMID 23939923 DOI: 10.1002/cmdc.201300311  0.611
2013 Roberts SA, Saha B, Frett B, Li HY. (Z)-N-tert-Butyl-2-(4-meth-oxy-anilino)-N'-(4-meth-oxy-phen-yl)-2-phenyl-acetimidamide. Acta Crystallographica. Section E, Structure Reports Online. 69: o902. PMID 23795077 DOI: 10.1107/S1600536813012877  0.606
2013 Wang Y, Kaiser CE, Frett B, Li HY. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. Journal of Medicinal Chemistry. 56: 5219-30. PMID 23566315 DOI: 10.1021/jm3017706  0.652
2001 Li HY, Qiu YL, Moyroud E, Kishi Y. Synthesis of DNA Oligomers Possessing a Covalently Cross-Linked Watson-Crick Base Pair Model. Angewandte Chemie (International Ed. in English). 40: 1471-1475. PMID 29712372 DOI: 10.1002/1521-3773(20010417)40:8<1471::Aid-Anie1471>3.0.Co;2-I  0.43
2001 Li HY, Qiu YL, Moyroud E, Kishi Y. Synthesis of DNA Oligomers Possessing a Covalently Cross-Linked Watson-Crick Base Pair Model Financial support from the National Institutes of Health (Grant: NS 12108) is gratefully acknowledged. Angewandte Chemie (International Ed. in English). 40: 1471-1475. PMID 11317306 DOI: 10.1002/1521-3773(20010417)40:8<1471::AID-ANIE1471>3.0.CO;2-I  0.422
Show low-probability matches.